Medical Doctor Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

John McClure

Cardiovascular Disease Saginaw, MI Medical Doctor

NPI 1427091123 CMS profile 337272

5375 Hampton Pl, Saginaw, MI 48604

Open in the dashboard

General payments

$33,212

147 records reported · program years 2019–2021

Research payments

$0

Paid to them · None reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$33,525 paid to institutions, not to them · program years 2019–2021

Through program year 2021, John McClure of Saginaw, MI is reported in the CMS Open Payments database as having received $33,212 across 147 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $33,525 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 92nd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $28,751 34
2020 General $3,579 57
2019 General $882 56

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John McClure
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to John McClure were reported at $0. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year John McClure Cardiovascular Disease median Middle half National median
2019 $882 $450 $127–$1,392 $163
2020 $3,579 $242 $77–$751 $114
2021 $28,751 $335 $101–$1,037 $132
2022 $0 $395 $121–$1,211 $149
2023 $0 $443 $136–$1,283 $160
2024 $0 $450 $136–$1,323 $164
2025 $0 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. AngioDynamics, Inc. $22,917 1 payment
  2. Esperion Therapeutics, Inc. $8,001 16 payments
  3. Cardiovascular Systems Inc. $431 10 payments
  4. Kowa Pharmaceuticals America, Inc. $240 19 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $232 13 payments
  6. Amarin Pharma Inc. $222 12 payments
  7. Janssen Pharmaceuticals, Inc $193 21 payments
  8. Novartis Pharmaceuticals Corporation $149 10 payments
  9. Medtronic Vascular, Inc. $112 3 payments
  10. Sanofi-Aventis U.S. LLC $111 9 payments
  11. Other $606 33 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Education $22,968 6 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $7,640 4 payments
  3. Food and Beverage $2,604 137 payments
Products named General payments · program years 2019–2021
  1. Auryon Laser System 100-120 Vac $22,917 1 payment
  2. NEXLETOL $8,001 16 payments
  3. NEXLIZET $7,869 7 payments
  4. Peripheral Orbital Atherectomy System $371 9 payments
  5. Bystolic $240 19 payments
  6. Livalo $240 19 payments
  7. JARDIANCE $232 13 payments
  8. Vascepa $208 11 payments
  9. XARELTO $193 21 payments
  10. PRADAXA $154 8 payments
  11. Other $1,073 63 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

147 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record